信迪利单抗转化治疗微卫星不稳定型III期结肠癌1例个案报道及文献复习  

Conversion Therapy with Sintilimab for dMMR/MSI-H Stage III Colon Cancer: A Case Report and Literature Review

作　　者：闫敏[1] 于丽[1] 何信佳[1] 赵园园[1] 

机构地区：[1]青岛大学附属医院肿瘤放疗科,山东 青岛

出　　处：《临床医学进展》2023年第2期2142-2147,共6页Advances in Clinical Medicine

摘　　要：既往研究表明,错配修复基因缺陷或微卫星不稳定型(dMMR/MSI-H)的晚期结直肠癌对传统化疗的反应较差。细胞程序性死亡受体(programmed death receptor 1, PD-1)/程序性死亡配体(programmed death ligand 1, PD-L1)信号通路阻断剂已成为这类肿瘤的有效治疗方法。我们报道一例III期dMMR/MSI-H结肠癌患者,接受了化疗联合信迪利单抗的转化治疗后顺利完成手术,并获得了MPR (病理性主要缓解,残余存活肿瘤 ≤ 10%)。Previous studies have shown that advanced colorectal cancer with mismatch repair gene defect or microsatellite instability (dMMR/MSI-H) has poor response to traditional chemotherapy. Pro-grammed death receptor (PD-1)/Programmed death ligand 1 (PD-L1) signal pathway blocker has become an effective therapy for this type of tumor. We report a patient with stage III dMMR/MSI-H colon cancer who successfully completed the operation after receiving chemotherapy combined with sintilimab conversion therapy and obtained MPR (pathological major response, residual sur-vival tumor ≤ 10%).

关 键 词：转化治疗 结直肠癌 免疫治疗 信迪利单抗 微卫星高度不稳定型 

分 类 号：R73[医药卫生—肿瘤]